Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Finasteride tablets from the National Medical Products Administration, which is expected to enhance the company's product portfolio and explore new market opportunities [1] Group 1 - The drug registration certificate for Finasteride tablets was obtained on August 2025 [1] - The approval is seen as beneficial for the company to diversify its product range [1] - The move is aimed at expanding into new market sectors [1]

每经AI快讯，8月5日，新华制药(000756.SZ)公告称，公司全资子公司新达制药收到国家药品监督管理 局核准签发的非那雄胺片《药品注册证书》。非那雄胺片适用于治疗和控制良性前列腺增生（BPH）以 及预防泌尿系统事件，属于《国家基本医疗保险、工伤保险和生育保险药品目录 (2025年)》乙类品种。 2024年中国公立医疗机构非那雄胺片销售额约人民币14.5亿元。新达制药的非那雄胺片于2025年8月取 得药品注册证书，有利于公司丰富产品系列，开拓新的市场领域。但药品销售业务易受到国内医药行业 政策变动、市场环境变化等因素影响，存在不确定性。 （文章来源：每日经济新闻） ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval for the registration of Finasteride tablets, which will enhance its product portfolio and open new market opportunities [1] Group 1 - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Finasteride tablets from the National Medical Products Administration [1] - The registration certificate for Finasteride tablets was granted in August 2025, indicating a future product launch [1] - This development is expected to contribute positively to the company's growth by diversifying its product offerings [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Finasteride tablets, which are used to treat benign prostatic hyperplasia (BPH) and prevent urinary system events [1] Company Summary - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., is responsible for the newly approved Finasteride tablets [1] - Finasteride tablets are indicated for reducing the risk of acute urinary retention and the need for surgical procedures such as transurethral resection of the prostate (TURP) and prostatectomy [1] - The medication is designed to shrink enlarged prostates, improve urinary flow, and alleviate symptoms associated with prostatic hyperplasia [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 山 東 新 華 製 藥 股 份 有 限 公 司 （ 「 本 公 司 」 ） 將 於 2025 年 8 月 6 日 在 巨 潮 資 訊 網 （http://www.cninfo.com.cn）刊登的本公司《關於子公司獲得非那雄胺片藥品註冊證書的公告》, 茲載列有關文檔之中文版，以供參閱。 承董事會命 山東新華製藥股份有限公司 賀同慶 董事長 中國 淄博 2025年8月5日 於本公告日期，本公司董事會之成員如下： | 執行董事： | | 獨立非執行董事： | | --- | --- | --- | | 賀同慶先生（董事長） | | 潘廣成先生 ...

3、港股通5日占比增持榜（前10名） 智通财经APP获悉，根据2025年8月4日披露数据，恆生中国企业（02828）、安德利果汁（02218）、美 中嘉和（02453）港股通持股占比增加值最大，分别增加6.53%、2.56%、2.52%；国联民生（01456）、 长飞光纤光缆（06869）、山东新华製药股份（00719）港股通持股占比减少值最大，分别减 少-1.64%、-1.15%、-1.03%。 在最近有统计数据的5个交易日内，恆生中国企业（02828）、长飞光纤光缆（06869）、山东墨龙 （00568）港股通持股占比增加值最大，分别增加14.25%、11.93%、6.52%；山东新华製药股份 （00719）、白云山（00874）、重庆钢铁股份（01053）港股通持股占比减少值最大，分别减 少-4.86%、-2.18%、-1.98%。 具体数据如下（交易所数据根据T+2日结算）： 1、港股通最新日占比增持榜（前20名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 恆生中国企业(02828) | +6.53% | 14.73% | | 安德利果汁(0221 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 山東新華製藥股份有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00719 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 195,000,000 | RMB | | 1 | RMB | | 195,000,000 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 195,000,000 | RMB | | 1 | RMB | | 195,000,000 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | ...

智通财经APP获悉，根据2025年7月31日披露数据，锦欣生殖（01951）、长飞光纤光缆（06869）、美 中嘉和（02453）港股通持股占比增加值最大，分别增加2.58%、2.38%、2.29%；上海復旦（01385）、 山东新华製药股份（00719）、钧达股份（02865）港股通持股占比减少值最大，分别减 少-1.70%、-1.37%、-1.25%。 在最近有统计数据的5个交易日内，宜搜科技（02550）、长飞光纤光缆（06869）、恆生中国企业 （02828）港股通持股占比增加值最大，分别增加14.75%、11.72%、7.36%；山东新华製药股份 （00719）、亚盛医药-B（06855）、重庆钢铁股份（01053）港股通持股占比减少值最大，分别减 少-3.89%、-2.94%、-2.70%。 具体数据如下（交易所数据根据T+2日结算）： 1、港股通最新日占比增持榜（前20名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 锦欣生殖(01951) | +2.58% | 51.76% | | 长飞光纤光缆(06869) | +2.38% | 44.07 ...

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating which companies have seen the largest increases and decreases in shareholding percentages. Group 1: Increased Holdings - Changfei Optical Fiber Cable (06869) saw the largest increase in holdings, up by 3.06% to a total holding of 41.69% [1][2] - Kanglong Chemical (03759) increased by 2.36%, reaching a holding of 54.24% [1][2] - Yisou Technology (02550) rose by 1.80%, with a current holding of 58.01% [1][2] - Other notable increases include China Zhongjin (01880) with a 0.78% increase to 41.73% and Shanghai Electric (02727) with a 0.76% increase to 43.36% [2] Group 2: Decreased Holdings - Shandong Xinhua Pharmaceutical (00719) experienced the largest decrease, down by 1.74% to a holding of 46.02% [1][3] - Southern Hengsheng Technology (03033) decreased by 0.95%, now holding 61.82% [1][3] - Jihong Co., Ltd. (02603) saw a reduction of 0.91%, with a current holding of 37.85% [1][3] - Other significant decreases include Junshi Biosciences (01877) down by 0.76% to 50.62% and New China Life Insurance (01336) down by 0.71% to 53.23% [3][4] Group 3: Five-Day Changes - Over the last five trading days, Yisou Technology (02550) had the highest increase of 13.77%, reaching 58.01% [5] - Changfei Optical Fiber Cable (06869) increased by 9.53% to 41.69% [5] - The Hang Seng China Enterprises Index (02828) rose by 5.73%, now at 7.19% [5] - Other notable increases include China Energy Construction (03996) up by 5.39% to 21.41% [5] Group 4: Twenty-Day Changes - In the last twenty days, Haotian International Construction (01341) saw the largest increase of 33.88%, reaching 59.80% [8] - Jihong Co., Ltd. (02603) increased by 26.53% to 37.85% [8] - Yisou Technology (02550) rose by 19.75% to 58.01% [8] - Other significant increases include Oriental Electric (01072) up by 15.27% to 43.05% [8] Group 5: Summary of Trends - The data indicates a trend of increasing foreign investment in certain technology and pharmaceutical companies, while traditional sectors like pharmaceuticals and steel are experiencing reductions in foreign holdings [1][5][8]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. actively participated in a voluntary blood donation campaign, demonstrating corporate social responsibility and employee engagement [1] Group 1: Company Initiatives - The company organized a blood donation event involving its first and second plants and the security department, showcasing a collective effort to contribute to society [1] - A total of 103 employees participated in the blood donation, contributing 38,450 milliliters of blood, highlighting the company's commitment to social causes [1] Group 2: Employee Engagement - Employees expressed a sense of fulfillment and purpose in donating blood, with one employee mentioning he has donated four times and plans to continue annually [1] - The event fostered a sense of community and solidarity among employees, reinforcing the company's internal cohesion and shared values [1]